Revive Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Revive Therapeutics's earnings have been declining at an average annual rate of -5.5%, while the Pharmaceuticals industry saw earnings growing at 46% annually.
Anahtar bilgiler
-5.5%
Kazanç büyüme oranı
12.0%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 23.1% |
Gelir büyüme oranı | n/a |
Özkaynak getirisi | -77.7% |
Net Marj | n/a |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Gelir ve Gider Dağılımı
Revive Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 0 | -6 | 2 | 1 |
31 Mar 24 | 0 | -4 | 2 | 1 |
31 Dec 23 | 0 | -4 | 2 | 2 |
30 Sep 23 | 0 | -5 | 2 | 3 |
30 Jun 23 | 0 | -6 | 2 | 4 |
31 Mar 23 | 0 | -8 | 2 | 6 |
31 Dec 22 | 0 | -12 | 2 | 10 |
30 Sep 22 | 0 | -15 | 3 | 12 |
30 Jun 22 | 0 | -18 | 3 | 15 |
31 Mar 22 | 0 | -24 | 7 | 15 |
31 Dec 21 | 0 | -22 | 8 | 13 |
30 Sep 21 | 0 | -20 | 8 | 11 |
30 Jun 21 | 0 | -20 | 12 | 7 |
31 Mar 21 | 0 | -14 | 9 | 4 |
31 Dec 20 | 0 | -12 | 9 | 2 |
30 Sep 20 | 0 | -10 | 7 | 1 |
30 Jun 20 | 0 | -5 | 3 | 0 |
31 Mar 20 | 0 | -3 | 2 | 0 |
31 Dec 19 | 0 | -1 | 1 | 0 |
30 Sep 19 | 0 | -1 | 1 | 0 |
30 Jun 19 | 0 | -1 | 1 | 0 |
31 Mar 19 | 0 | -1 | 1 | 0 |
31 Dec 18 | 0 | -2 | 1 | 0 |
30 Sep 18 | 0 | -2 | 1 | 0 |
30 Jun 18 | 0 | -2 | 1 | 0 |
31 Mar 18 | 0 | -2 | 2 | 0 |
31 Dec 17 | 0 | -2 | 1 | 0 |
30 Sep 17 | 0 | -2 | 1 | 0 |
30 Jun 17 | 0 | -2 | 1 | 0 |
31 Mar 17 | 0 | -2 | 1 | 1 |
31 Dec 16 | 0 | -2 | 1 | 1 |
30 Sep 16 | 0 | -2 | 1 | 1 |
30 Jun 16 | 0 | -3 | 1 | 2 |
31 Mar 16 | 0 | -3 | 1 | 2 |
31 Dec 15 | 0 | -3 | 1 | 1 |
30 Sep 15 | 0 | -3 | 1 | 1 |
30 Jun 15 | 0 | -2 | 1 | 1 |
31 Mar 15 | 0 | -2 | 1 | 1 |
31 Dec 14 | 0 | -2 | 1 | 0 |
30 Sep 14 | 0 | -2 | 1 | 0 |
30 Jun 14 | 0 | -1 | 1 | 0 |
31 Mar 14 | 0 | -1 | 1 | 0 |
Kaliteli Kazançlar: RVV is currently unprofitable.
Büyüyen Kar Marjı: RVV is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: RVV is unprofitable, and losses have increased over the past 5 years at a rate of 5.5% per year.
Büyüme Hızlandırma: Unable to compare RVV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: RVV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Özkaynak Getirisi
Yüksek ROE: RVV has a negative Return on Equity (-77.69%), as it is currently unprofitable.